Disclosed is a composition for preventing, treating or ameliorating a viral infection disease, which is safe for human application since the safety of a reactive oxygen species production inhibitor and a reactive oxygen species scavenger has already been verified. The disclosure utilizes inversely the mechanism of viruses which induces oxidative damage of a host cell and then activates viral replication and infection. Although not having direct specificity to a specific virus like existing vaccines, the composition can effectively inhibit proliferation of all viruses including oxidative stress, regardless of virus type or mutations. It can be applied as a sub-universal infection inhibitor and therapeutic agent as a limited alternative to vaccines that must be newly developed each year due to emergence of new viruses or viral mutations, and is expected to be used as a preventive agent or auxiliary agent to prevent epidemics.

The disclosure provides methods of treating gout in renal transplant recipients comprising administering pegloticase as described herein. Also provided are methods of reducing immunogenicity of pegloticase and prolonging the urate lowering effect comprising administration of pegloticase. Also provided are methods of preserving kidney function as a result of administration of the pegloticase.

The disclosure provides methods of treating gout in renal transplant recipients comprising administering pegloticase as described herein. Also provided are methods of reducing immunogenicity of pegloticase and prolonging the urate lowering effect comprising administration of pegloticase. Also provided are methods of preserving kidney function as a result of administration of the pegloticase.

The disclosure provides methods of treating gout in renal transplant recipients comprising administering pegloticase as described herein. Also provided are methods of reducing immunogenicity of pegloticase and prolonging the urate lowering effect comprising administration of pegloticase. Also provided are methods of preserving kidney function as a result of administration of the pegloticase.

In aspects, the present disclosure provides a method of treating or preventing a uterine fibroid in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an agent that modulates an N6-methyladenosine (m6A) regulator.

In aspects, the present disclosure provides a method of treating or preventing a uterine fibroid in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an agent that modulates an N6-methyladenosine (m6A) regulator.

The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.

The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.

Compositions comprising (i) lactate oxidase (LOX) and Catalase (CAT), preferably in a 1:1 molar ratio; or (ii) a fusion polypeptide comprising both LOX and CAT, e.g., LOXCAT, and methods of use thereof for reducing blood lactate levels, increasing blood pyruvate levels, and/or decreasing blood lactate/pyruvate ratio in a subject.

Provided is a new means for administering a valuable substance having a fat dissolving action. A microneedle preparation including at least one of a lipolytic agent, a fat dissolving agent, or a fat metabolism promoting agent, the microneedle preparation being intended for fat reduction and/or partial slenderizing and/or skin tightening, and a microneedle preparation including a microneedle array containing a water-soluble polymer as a base and one or more selected from the group consisting of a lipase, a phosphatidylcholine, and deoxycholic acid.